|
NEW YORK, NY (October 8, 2002) - It is the American Society for Aesthetic
Plastic Surgery's (ASAPS') position that, currently, lipoplasty
(liposuction) is the only proven method for the permanent reduction of fat
deposits. Recently, however, there have been articles in popular consumer
magazines describing the injection of phosphatidylcholine, a phospholipid
that is known by the trade name of Lipostabil. Claims state that this
substance dissolves fat without the need for surgical intervention. ASAPS
cautions that the safety and effectiveness of this procedure are unproven.
Licensed physicians may legally offer treatments involving off-label uses of
many pharmacologic substances, as long as such substances have been approved
by the Food and Drug Administration for other uses and there is no specific
prohibition of the intended off-label use. Currently, however, Lipostabil
is not approved for any use in this country. In addition, there does not
appear to be sufficient scientific and clinical data to substantiate the
safety and effectiveness of phosphatidylcholine (Lipostabil) as a
fat-dissolving treatment.
Lipostabil was not developed as a fat-dissolving agent. . The only published
study using phosphatidylcholine for this purpose treated only 30 patients
(on their lower lids), with a maximum follow-up of two years. The published
photographs demonstrating visible reduction of the very small amounts of
excess fat contained in the lower eyelid seem promising, but the study
lacked controls, and the results have yet to be duplicated in other
peer-reviewed studies.
Specific questions regarding phosphatidylcholine (Lipostabil) should be
answered before its safe use on patients can be assured:
-
How can it be
assured that the appropriate amount of fat - neither too little nor too
much -- is dissolved? (It should be noted that current techniques in
cosmetic eyelid surgery tend to favor greater preservation of fat tissue
in the lower eyelid, with optimal correction often achieved by a
combination of minimal fat removal and repositioning or suturing of fatty
tissues.)
-
If
phosphatidylcholine dissolves fatty tissue, does it also dissolve other
tissue? How is delivery of the substance limited to only the target
tissues? While phosphatidylcholine is a naturally occurring compound that
is present in the body, what problems might be encountered by adding an
uncontrolled amount of the substance?
-
The injection
of phosphatidylcholine into subcutaneous tissues can potentially trigger
the release of enzymes (lipases), which break down lipids or act as an
emulsifier or detergent to dissolve cell membranes and intracellular fats.
Either of these mechanisms may trigger the release of histamines, which
tend to produce itching and redness; these may be short-term side effects,
but are there also long-term side-effects? Given the chemical makeup of
the substance, is there the possibility that side-effects could include
leakage of cell membranes or even cell death?
A great deal of the currently published research in aesthetic plastic
surgery focuses on the development of minimally invasive procedures that can
improve a patient's appearance with fewer risks and shorter recovery than
traditional surgery. The way in which safety and effectiveness of new
procedures is determined, in preparation for their widespread use in
properly selected patients, is through careful scientific and clinical
research. Such research is evaluated through publication of results in
reputable, peer-reviewed medical journals and presentation of results at
medical meetings such as those sponsored by ASAPS and other accredited
Continuing Medical Education sponsors.
As the leading society of plastic surgeons certified by the American Board
of Plastic Surgery, who specialize in aesthetic (cosmetic) surgery, ASAPS
believes that research into new cosmetic surgical and nonsurgical treatments
with potential benefits to patients is important and should be conducted
responsibly by qualified physicians, according to established scientific and
ethical guidelines that are accepted medical practice in this country. If
patients are involved in clinical trials of new procedures, they must be
provided with adequate data for their full informed consent. The Aesthetic
Surgery Research and Education Foundation (ASERF), in conjunction with ASAPS,
observes these guidelines in funding research and evaluating new
techniques/technology in order to help ensure patient safety and treatment
efficacy.
As the leading provider of Continuing Medical Education in cosmetic plastic
surgery to board-certified plastic surgeons, ASAPS encourages
open-mindedness in regard to any new modalities, but the public must be
cautious in regarding such treatments as "harmless" without scientific
evidence of their safety and efficacy. It may take some time before
important questions about the use of phosphatidylcholine for body contouring
are answered by independent researchers. |